CDK4 and breast carcinoma: Thus far, CDK4/6 inhibitors (CDK4/6i) have proved the most promising, with three inhibitors (palbociclib, ribociclib, and abemaciclib) currently approved by the U.S. Food and Drug Administration (FDA) for oestrogen receptor (ER)-positive breast cancer treatment.